UBS O'Connor’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

UBS O'Connor’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,000	Closed	-$510K	–	671
2023 Q2	$510K	Sell	5,000 -250	-5%	-$23.7K	0.01%	443
2023 Q1	$477K	Buy	+5,250	New	+$308K	0.01%	468
2019 Q1	–	Sell	-17,178	Closed	-$964K	–	165
2018 Q4	$964K	Buy	17,178 +4,874	+40%	+$298K	0.03%	167
2018 Q3	$1.01M	Buy	+12,304	New	+$867K	0.02%	203
2017 Q4	–	Sell	-83,364	Closed	-$2.59M	–	402
2017 Q3	$2.59M	Buy	+83,364	New	+$2.51M	0.04%	244

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS O'Connor's RETA Position: Q3 2023 in Review

UBS O'Connor sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,000 shares — an estimated $510K sold.

UBS O'Connor first reported a position in RETA in Q3 2017 and held it in 5 quarters. The position peaked at $2.59M in Q3 2017. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

UBS O'Connor reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
UBS O'Connor sold 5,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $510K.
UBS O'Connor first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 5 quarters.
UBS O'Connor's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.59M in Q3 2017.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on UBS O'Connor's 13F filing for Q3 2023, filed 14 Nov 2023.